Aims Multi-drug resistant Plasmodium falciparum malaria is a rapidly increasing problem in the world, particularly Thailand. Practical antimalarial regimens which are highly effective against multi-drug resistant parasites with short-term course of administration are needed. In this study, we assessed the patient compliance of a short course regimen using artemether-mefloquine. Methods Clinical effectiveness (efficacy, tolerability and patient compliance) of a 2-day regimen of artemether-mefloquine was evaluated in 126 patients with acute uncomplicated falciparum malaria who were attending the two malaria clinics in an area of highly multi-drug resistant P. falciparum malaria (Thai-Myanmar border). Patients were treated with a single oral dose of 300 mg artemether on the day of attendance. Two additional doses of mefloquine were given for home treatment on the following day (750 and 500 mg after breakfast and lunch, respectively). Results The combination regimen was effective, with a cure rate of 92.6%. Based upon the concentrations of whole blood mefloquine on day-2, compliance for this 2 day regimen of artemether-mefloquine was 98.1% (full compliance 86.8%, partial compliance 11.3%, non-compliance 1.9%). Conclusions We conclude that the 2 day regimen of artemether-mefloquine is, at present, a good alternative regimen for the treatment of uncomplicated multi-drug resistant falciparum malaria.
take the drug (two doses of mefloquine) unsupervised at Introduction home and there may be a relatively high incidence of recrudescence due to incomplete treatment. Multi-drug resistant Plasmodium falciparum malaria is a rapidly increasing problem in Thailand, particularly in the border
In the present study, we have assessed the patient compliance of this short-course regimen of artemetherregions [1] . In these areas, the efficacy of mefloquine, which has been used by the Malaria Control Programme as a firstmefloquine in the treatment of multi-drug resistant, uncomplicated falciparum malaria under field conditions. line treatment for uncomplicated falciparum malaria, is lower than 50%, even when given at a higher dose of 1250 mg or 25 mg kg −1 [2-5]. A 7 day course of quinine-tetracycline, Methods which is the standard treatment, gives a high cure rate of
The study was undertaken at the two malaria clinics in over 95% in hospital-based treatment [6] [7] , but this regimen Mae-Sot District, Tak Province (a well-documented area of is associated with high incidence of adverse effects and poor multi-drug resistant P. falciparum) during November 1994 patient compliance when applied for general use outside a and May 1995. Malaria is a serious imported medical hospital environment. Thus, practical antimalarial regimens problem with a peak incidence during May-August and which are highly effective against multi-drug resistant November-January of each year. Most patients are adult parasites with short-term course of administration are needed.
males, and approximately 80% of infections are caused by A 2 day course of treatment with artemether followed by P. falciparum. The study was approved by the Ethics a longer half-life drug, i.e. mefloquine (a single oral dose of Committee of the Faculty of Tropical Medicine, Mahidol 300 mg artemether initially, followed by two doses of 750 University, and the National Ethics Committee, Ministry of and 500 mg mefloquine at 24 and 30 h apart) has been Public Health. shown to be highly effective against multi-drug resistant One hundred and twenty-six patients (109 males, 17 falciparum malaria in a hospital setting [8] . However, the females) presenting with symptomatic uncomplicated malaria effectiveness of this regimen cannot be verified when applied (asexual form parasitaemia 200-5050 per 200 WBC), who clinically in the rural tropics, as the patients will have to had no history of liver or kidney diseases and no previous history of antimalarial treatment during the previous 4
Correspondence: Professor Juntra Karbwang, Clinical Pharmacology Unit, Faculty of Tropical Medicine, 420/6 Rajvithi Road, Pyathai, Bangkok 10400, Thailand weeks, were included in the study. Median (range) values for age and weight of the patients were 29 (15-68) years most common adverse effects were nausea (6.6%), dizziness (24.6%), vomiting (6.6%), headache (6.6%), and diarrhoea and 53 (45-64) kg.
Prior to treatment (day 0) a blood sample (2 ml) was (3.3%). All occurred during the day of mefloquine administration (day 1). None vomited after an initial dose of taken for the determination of mefloquine concentrations. Patients were treated with a 2 day course of the combination artemether. Of the 108 patients whose mefloquine concentrations were measured, 55 (50.9%) had undetectable baseline artemether-mefloquine. The initial dose of 300 mg artemether (ArtenamA, Arenco n.v., 50 mg per tablet ) was mefloquine level, whereas 23 (21.3%), 18 (16.7%) and 12 (11.1%) cases, respectively, had concentrations of less than administered under supervision, with the second and third doses of mefloquine (750 and 500 mg: LariamA, Roche, 100, between 100 and 500, and more than 500 mg l −1
[median (range): 46.5 (13-85) vs 332 (108-496) vs 649 250 mg per tablet) being administered at home the following day after breakfast and lunch, respectively (4-6 h interval ).
(511-1542) mg l
]. Figure 1 describes median whole blood mefloquine A full dose of artemether was repeated if vomiting occurred within the first hour of intake. When necessary, symptomatic concentrations in 20 hospitalised patients who were taking the drug under supervision. Median (range) concentrations treatment with an antipyretic paracetamol and, an antiemetic-dimenhydrinate (DramamineA) was administered.
on day 2 were 2262 (1198-3254) mg l −1 , with a 95% C.I.
of 1587-2572 mg l −1 (reference interval). Two, four and Patients were asked to return for follow-up on the second day of treatment (day 2), and on days 7, 14, 21, 28 and 42, two cases, respectively had baseline concentrations of <100, 100-500 and >500 mg l −1 . or at any time if fever or symptoms suggestive of malaria developed. At each visit, a parasite count was performed Since mefloquine has a very long half-life drug (14-21 days in patients), the decrease in the concentrations within (Giemsa-stain), and a detailed questionnaire for general symptoms was recorded. Blood samples were taken (2 ml) 2 days is insignificant and therefore day 2 concentrations in patients who had measurable baseline concentrations were for determination of mefloquine concentrations and compared with reference profiles (with frequent blood sampling estimated by substraction of baseline concentrations from the measured day 2 concentrations. Ninety-two patients at 0, 6, 12 h and on days 14, 21, 28, 35 and 42 after the initial dose of mefloquine) obtained from 20 hospitalised with home treatment had day 2 mefloquine concentrations within or above the reference interval (full compliance). male patients who were receiving the same regimen of artemether-mefloquine under supervision (at the Bangkok Fourteen cases exhibited concentrations below the reference interval, but two had severe vomiting within the first 1 h Hospital for Tropical Diseases). Whole blood samples were stored at −20°C until analysis by high-performance liquid of mefloquine intake. Twelve cases were therefore considered to show partial compliance. In two cases, mefloquine chromatography. The method has previously been described with intra-and inter-assay coefficients of variation of less concentration was undetectable (non-compliance); both had complete parasite clearance on day 2 (3 days after the initial than 5%, with limit of quantification of 10 mg l −1 [9] .
Patients failing to respond were retreated with a 5 day dose of artemether) but were lost to follow-up afterwards. Compliance with this 2 day combination was therefore course of artemether (300 mg on the first day, followed by 100 mg for another 4 days). Those who developed 98.1% [full compliance 86.8% (92/106), partial compliance 11.3% (12/106), non-compliance 1.9% (2/106)]. Plasmodium ( P.) vivax malaria in their peripheral blood during the follow-up period were treated with 300 mg Recrudescence occurred in three patients with full compliance and one case of partial compliance (Figure 1 ). At the (base) of chloroquine to suppress symptoms and a full course of treatment was given at the end of the study period time of recrudescence, only two patients had measurable concentrations of mefloquine on days 22 and 25 (655 and (chloroquine 1500 mg given over 48 h, followed by 15 mg (base) of primaquine daily for 14 days).
541 mg l −1 : Figure 1 ).
The clinical outcome from of a 2 day course of artemether-mefloquine was evaluated in the group of Discussion patients presenting to malaria clinics in Mae-Sot who completed the 42 day follow-up period. Treatment failure A good initial response was observed in all patients where parasitaemia was cleared within 3 days after the initial dose cases were classified (RI, RII or RIII) according to the World Health Organization criteria [10] . Patient compliance of artemether. Parasite clearance was observed in the two patients who did not take mefloquine (non-compliance). was evaluated based upon day 2 concentrations of mefloquine in the reference profiles obtained from the hospitalised This suggests that with a single dose of artemether, parasites can be cleared transiently from the circulation although pataients. Statistical analysis of the data was performed by a Mann-Whitney-U test with a significance level of P=0.05.
early recrudescence might be expected [11] . The present combination of artemether-mefloquine improved the cure rate from approximately 50% with mefloquine alone [5] to Results 92.6%, but, more importantly, reduced the risk of high grade resistance (RII, RIII) to zero. The lower cure rate of All patients had a rapid initial response to treatment with parasites cleared from peripheral blood within 3 days of an this short course of artemether-mefloquine compared with that previously reported by our group [8, 12] highlights the initial dose of artemether. Fifty-four patients completed the 42 day follow-up period. Four patients recrudesced on days rapidly increasing incidence of highly mefloquine resistant P. falciparum in this area. Using mefloquine alone against 14, 22 and 25 (2, 1 and 1 cases, respectively). One patient developed P. vivax infection on day 28. The cure rate for falciparum malaria in this area is no longer effective as evidenced by the high failure rate from this drug in the this combination regimen was therefore 92.6% (50/54). The tetracycline, where prolonged drug administration or a
